Obeticholic Acid Market Report 2026

Obeticholic Acid Market Overview

• Obeticholic Acid market size has reached to $1.01 billion in 2025 • Expected to grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 12.7% • Growth Driver: Rising Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Increasing Cases Of NAFLD And Alcohol-Related Liver Conditions • Market Trend: FDA Moves Forward With Approval EMA Recommends Revoking Marketing Authorization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Obeticholic Acid Market?

Obeticholic acid is a medication primarily used in the treatment of liver diseases, especially for patients with primary biliary cholangitis (PBC), a chronic liver disease. It is a synthetic bile acid that works by activating a receptor called the farnesoid X receptor (FXR), which helps to regulate bile acid production, liver function, and inflammation. The main product types in the obeticholic acid included tablets, capsules, and other forms. Tablets are solid dosage forms designed for convenient oral administration. The drugs distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These are used to treat nonalcoholic steatohepatitis, primary biliary cholangitis, and other conditions.

What Is The Obeticholic Acid Market Growth Forecast?

The obeticholic acid market size is expected to see rapid growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing NASH patient population, expansion of liver disease drug pipelines, improved diagnostic screening adoption, rising investment in hepatology research, global expansion of oral liver therapies. Major trends in the forecast period include rising prevalence of chronic liver diseases, increasing adoption of FXR agonist therapies, growing focus on disease-modifying liver drugs, expansion of nonalcoholic steatohepatitis research, increasing use of oral hepatology treatments.

Global Obeticholic Acid Market Segmentation

1) By Product Type: Immediate-Release Tablets, Modified-Release Tablets, Film-Coated Tablets 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications Subsegments: 1) By Immediate-Release Tablets: Standard Oral Tablets, Low-Dose Strength Tablets 2) By Modified-Release Tablets: Controlled Exposure Tablets, Once-Daily Optimized Release Tablets 3) By Film-Coated Tablets: Taste-Masked Tablets, Gastrointestinal-Tolerant Tablets

What Is The Driver Of The Obeticholic Acid Market?

The rising prevalence of liver diseases is expected to propel the growth of the obeticholic acid market going forward. Liver diseases are conditions that affect the liver's ability to function properly. The rising prevalence of liver diseases is due to excessive alcohol consumption, which can lead to liver inflammation, cirrhosis, and liver failure by causing damage to liver cells and impairing the organ's ability to function properly. Obeticholic acid helps liver disease patients by activating the farnesoid X receptor (FXR), which reduces bile acid accumulation, decreases liver inflammation, and slows fibrosis progression, ultimately improving liver function. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, the number of premature deaths from alcoholic liver disease increased by 3.6%, reaching 5,984, up from 5,776 in 2022. Therefore, the rising prevalence of liver diseases is driving the growth of the obeticholic acid industry.

Key Players In The Global Obeticholic Acid Market

Major companies operating in the obeticholic acid market are Intercept Pharmaceuticals Inc., Genfit, Gilead Sciences Inc., Pfizer Inc., Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Alembic Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Cadila, Teva Pharmaceutical Industries Ltd., WuXi AppTec, Viva Life Sciences, Omgene Life Sciences Pvt. Ltd., Enanta Pharmaceuticals, Novo Nordisk A/S, AstraZeneca plc, Roche Holding AG, Sanofi S.A.

Global Obeticholic Acid Market Trends and Insights

Major companies operating in the obeticholic acid market are developing innovative products, such as farnesoid X receptor (FXR) agonist to enhance liver disease treatment and improve patient outcomes. A farnesoid X receptor (FXR) agonist is a compound that activates the FXR, a nuclear receptor involved in regulating bile acid metabolism, inflammation, and fibrosis in the liver. Farnesoid X receptor (FXR) agonists help improve liver function and are used in the treatment of conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For instance, in February 2024, Intercept Pharmaceuticals Inc., a US-based biopharmaceutical company, announced that the announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva to treat individuals with primary biliary cholangitis (PBC). The FDA's acceptance of the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) signifies regulatory progress toward validating its clinical benefits in treating PBC.

What Are Latest Mergers And Acquisitions In The Obeticholic Acid Market?

In November 2023, Alfasigma, an Italy-based pharmaceutical company, acquired Intercept Pharmaceuticals, Inc. for USD 19.00 per share in cash. Through this acquisition, Alfasigma aims to strengthen its presence in the U.S. and expand its portfolio in gastroenterology and hepatology. Intercept Pharmaceuticals, Inc. is a US-based biopharmaceutical company focused on developing therapies for rare and serious liver diseases, including primary biliary cholangitis (PBC), and its lead product, Ocaliva.

Regional Insights

North America was the largest region in the Obeticholic Acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Obeticholic Acid Market?

The obeticholic acid market consists of sales of products including tablets, generic obeticholic acid, ocaliva support services, patient education kits, and obeticholic acid + ursodeoxycholic acid (UDCA). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Obeticholic Acid Market Report 2026?

The obeticholic acid market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the obeticholic acid industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.